Iblh.Psx
IBLH.PSX operates in the drug retailing sector, providing pharmaceutical and healthcare products to consumers through its retail network.
Business. IBLH.PSX operates in the drug retailing sector, providing pharmaceutical and healthcare products to consumers through its retail network.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IBLH.PSX operates in the drug retailing sector, providing pharmaceutical and healthcare products to consumers through its retail network.
IBLH.PSX maintains a relatively strong liquidity position, with a current ratio of 2.02, indicating that it has twice as many current assets as current liabilities. However, the company reported negative operating cash flow of -259.67 million, which raises concerns about its ability to generate cash from operations. Free cash flow stands at 197.25 million, suggesting that the company is still able to fund operations and potentially reinvest in the business after capital expenditures.
Profitability metrics show a return on equity (ROE) of 8.97% and a return on assets (ROA) of 5.2%, which are key indicators of the company's efficiency in generating returns for shareholders and asset utilization. These figures should be compared to the industry median to determine whether IBLH.PSX is outperforming or underperforming its peers.
The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.07, indicating that it is not heavily leveraged. Long-term debt is minimal at 158.98 million, and total liabilities amount to 1.69 billion, which is significantly lower than total assets of 4.01 billion. This suggests that the company has a strong equity base and is not overly reliant on debt financing.
Geographically and segment-wise, IBLH.PSX's revenue concentration is not disclosed in the available data, but the company's operations are primarily focused on drug retailing. The lack of detailed segment data limits the ability to assess the performance of individual business lines or regions.
Looking ahead, the company's growth trajectory is uncertain due to the negative operating cash flow and the absence of detailed revenue history. The outlook for the current fiscal year and the next fiscal year is not provided, but the company's ability to maintain or grow revenue will depend on its operational efficiency and market conditions.
Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. However, the risk assessment indicates a medium liquidity risk and a low dilution risk, with the key flag being that net cash is negative after subtracting total debt. This suggests that the company may need to manage its cash flow more effectively to avoid liquidity constraints.
- IBLH.PSX has a strong equity base and a conservative capital structure, with a debt-to-equity ratio of 0.07.
- The company's liquidity position is moderate, with a current ratio of 2.02, but it reported negative operating cash flow of -259.67 million.
- Profitability metrics, including ROE of 8.97% and ROA of 5.2%, indicate that the company is generating reasonable returns for shareholders and asset utilization.
- The company's growth trajectory is uncertain due to the lack of detailed revenue history and the negative operating cash flow.
- The risk assessment highlights a medium liquidity risk and a low dilution risk, with the key flag being that net cash is negative after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IBLH.PSX Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Mufti Ziaul ul IslamChief Executive Officer, Executive Director